Compare Fidelity National Information Servcs Inc (FIS) vs IDEXX Laboratories, Inc. (IDXX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Fidelity National Information Servcs Inc vs IDEXX Laboratories, Inc. — how do they compare? Fidelity National Information Servcs Inc trades at $34.08 (market cap $17.71B), while IDEXX Laboratories, Inc. trades at $518 (market cap $40.43B). The key difference: IDEXX Laboratories, Inc. is far larger — about 2.3× Fidelity National Information Servcs Inc's market cap, and Fidelity National Information Servcs Inc pays a 5.13% dividend while IDEXX Laboratories, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Fidelity National Information Servcs Inc for 88 Days and IDEXX Laboratories, Inc. for 46 Days on average.
| FIS | IDXX | |
|---|---|---|
Market Cap | $17.71B | $40.43B |
Volume | 9,047,825 | 692,164 |
Sector | Technology | Health |
52-Week High | $68.57 | $766.68 |
52-Week Low | $32.44 | $504.70 |
Typical Hold Time | 88 Days | 46 Days |
Enterprise Value | $38.22B | $41.32B |
Dividend Yield | 5.13% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FIS trades at $34.04, up 0.65% on the day, with a bearish technical signal from moving averages and oscillators. The company's valuation metrics appear attractive with a P/E of 5.27 and P/S of 1.46, while recent earnings have shown beats in Q1 and Q2 2026. Revenue is projected to grow to $12.2B in 2026, with net income margin improving to 27.64%. Recent news highlights contract wins and platform modernizations, supporting growth momentum.
The outlook for FIS is cautiously optimistic, with strong analyst support (56.76% buy ratings) and a consensus price target of $47.15 implying significant upside. However, risks include a high debt-to-asset ratio of 39.06% in 2025 and volatile cash flow trends. Investors should weigh the low valuation against execution risks and macroeconomic pressures in the financial technology sector.
IDEXX Laboratories (IDXX) trades at $518.00, up 2.24% with strong earnings beats in recent quarters. The stock shows bearish technical signals but maintains robust fundamentals with 25.03% net margins and 74.21% ROE. Recent acquisitions like CoVetAI and product expansions highlight growth initiatives. Analyst consensus remains bullish with a $665 price target, though technical indicators suggest near-term caution.
Outlook remains positive driven by diagnostic innovation and recurring revenue growth, but faces headwinds from FX volatility and weaker U.S. vet visits. The 36.06 P/E ratio reflects premium valuation, requiring sustained execution. Risks include competitive pressures and insider selling, while institutional ownership trends show mixed signals.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Fidelity National Information Servcs Inc
Fidelity National Information Services' legacy operations provide core and payment processing services to banks, but its business has expanded over time. By acquiring Sungard in 2015, the company now provides record-keeping and other services to investment firms. With the acquisition of Worldpay in 2019, FIS now provides payment processing services for merchants and holds leading positions in the United States and United Kingdom. About a fourth of revenue is generated outside North America.
Read more on FIS →About IDEXX Laboratories, Inc.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →
